Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Debt Repayment

Cash used to repay borrowings during the period.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Debt Repayment · Q3 FY2026 · quarter ended Mar 2026

Debt repayment of $0 in Q3 FY2026

Q3 FY2026 debt repayment was $0. Trailing-twelve-month debt repayment was -$5.13M. Over 3 fiscal years it compounded at -30.6% a year.

Context

  • Debt repayment amounted to 14.4% of revenue in FY2025, up 12.7 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$1.28M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearMay 2025
-$18.56M-955.9% YoY
LTMMar 2026
-$5.13M— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-955.9%——
3-year CAGR-30.6%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(18.56M) USD
Year-over-year change
-955.9%

Debt Repayment vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Debt repayment amounts to 3.8% of revenue for LFCR, versus a peer median of 5.3%.
LFCR Competitors
Debt Repayment for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$13.52M CAD-93.9%—4.3%
CVRXCVRx, Inc.LTM Mar 2026$8.89M USD+5828.7%—15.1%
BIOABioAge Labs, Inc.LTM Mar 2026$6M USD+0.0%—58.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.13M USD—-30.6%3.8%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$5M USD+160.3%——
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.24M CAD+426.3%—1.4%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.15M USD+93.3%-52.2%5.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.64M EUR+4.7%-65.2%12.2%
IMMPImmutep LimitedFY2025A$270.67K AUD+19.5%+6.7%5.4%
SGHTSight Sciences, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding LFCR) —+19.5%-52.2%5.3%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Depreciation & Amortization19.87M18.06M13.18M7.95M8.03M
Deferred Income Tax(7.87M)(6.83M)357K163K0
Stock-Based Compensation3.36M2.61M3.61M6.2M10.16M
Change in Working Capital9.76M(3.1M)19.79M(3.7M)(4.7M)
Accounts Receivables5.78M(6.14M)10.82M(2.39M)(2.26M)
Inventory(2.82M)(2.18M)(14.81M)862K7.69M
Accounts Payables(5.98M)9.34M16.04M(6.68M)(1.67M)
Other Working Capital12.79M(4.13M)7.74M4.51M(8.45M)
Other Non-Cash Items23.65M83.38M45.19M(22.38M)25.02M
Operating Cash Flow16.47M(22.59M)(17.44M)257K(206K)
Capital Expenditures(25.22M)(29.94M)(21.48M)(18.4M)(13.42M)
Acquisitions (Net)073.5M16.67M07M
Purchases of Investments00000
Sales of Investments045.1M000
Other Investing Activities12.91M(8.7M)000
Investing Cash Flow(12.31M)79.96M(4.81M)(18.4M)(6.42M)
Debt Repayment7.47M(55.41M)3.12M2.17M(18.56M)
Common Stock Issued004.82M023.85M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(10.89M)(1.61M)(6.32M)5.34M1.13M
Financing Cash Flow(3.42M)(57.02M)39.7M7.51M6.42M
Effect of Forex Changes00000
Net Change in Cash742K348K17.45M(10.63M)(197K)
Free Cash Flow(8.75M)(52.53M)(38.92M)(18.14M)(13.62M)

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.